Clinuvel Pharmaceuticals Ltd
CUV: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$24.00 | Zblj | Xyhngdfbm |
Clinuvel Shares Appear Undervalued as Sales in Core Product Continue to Grow
Business Strategy and Outlook
Clinuvel’s strategy revolves around expanding its direct distribution for adult erythropoietic protoporphyria, or EPP, patients. This involves training and collaborating with doctors and accrediting the specialist skin centers they practice in to prescribe Scenesse. By focusing on distribution, Scenesse is more accessible to a greater number of patients, and supportive of organic top-line growth.